Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor

ibrutinib in mantle cell lymphoma patients

by Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman,

Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, and Laurence Elias

BloodVolume 122(14):2412-2424

October 3, 2013

©2013 by American Society of Hematology

Transient mobilization of lymphocytes in MCL patients treated with ibrutinib.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

CD19+CD5+ cells have decreased CXCR4, CD38, and Ki67 expression following ibrutinib treatment.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Ibrutinib inhibits migration of MCL cells beneath stromal cells (pseudo-emperipoiesis) and the formation of CXCL12-stimulated cortical actin.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Ibrutinib suppresses BCR- and coculture-stimulated signaling and cytokine and chemokine production of MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Ibrutinib inhibits BCR-activated adhesion of MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Ibrutinib inhibits CXCL12-/CXCL13-activated adhesion and migration of MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology

Ibrutinib inhibits BCR- and chemokine-induced adhesion of primary MCL cells.

Chang B Y et al. Blood 2013;122:2412-2424

©2013 by American Society of Hematology